EyePoint Pharmaceuticals Overview
- Year Founded
-
1987

- Status
-
Public
- Employees
-
144

- Stock Symbol
-
EYPT

- Investments
-
3
- Share Price
-
$6.50
- (As of Friday Closing)
EyePoint Pharmaceuticals General Information
Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Contact Information
Website
www.eyepointpharma.comCorporate Office
- 480 Pleasant Street
- Suite A-210
- Watertown, MA 02472
- United States
Corporate Office
- 480 Pleasant Street
- Suite A-210
- Watertown, MA 02472
- United States
EyePoint Pharmaceuticals Stock Performance
As of 14-Feb-2025, EyePoint Pharmaceuticals’s stock price is $6.50. Its current market cap is $444M with 68.3M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.50 | $6.31 | $5.90 - $29.45 | $444M | 68.3M | 914K | -$1.99 |
EyePoint Pharmaceuticals Financials Summary
As of 30-Sep-2024, EyePoint Pharmaceuticals has a trailing 12-month revenue of $45.7M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 170,656 | 998,897 | 8,488 | 333,562 |
Revenue | 45,713 | 46,018 | 41,404 | 36,939 |
EBITDA | (115,784) | (75,950) | (98,750) | (50,440) |
Net Income | (103,570) | (70,795) | (102,254) | (58,417) |
Total Assets | 300,917 | 355,184 | 180,356 | 263,372 |
Total Debt | 21,922 | 4,906 | 45,769 | 39,204 |
EyePoint Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
EyePoint Pharmaceuticals Comparisons
Industry
Financing
Details
EyePoint Pharmaceuticals Competitors (67)
One of EyePoint Pharmaceuticals’s 67 competitors is Novartis, a Corporation company based in Basel, Switzerland.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Novartis | Corporation | Basel, Switzerland | ||||
Landsteiner Scientific | Formerly PE-Backed | Toluca, Mexico | ||||
Swedish Orphan Biovitrum | Formerly VC-backed | Stockholm, Sweden | ||||
Merck & Co. | Corporation | Rahway, NJ | ||||
Cipla | Corporation | Mumbai, India |
EyePoint Pharmaceuticals Patents
EyePoint Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-D1043969-S1 | Ocular injector | Active | 20-Jan-2023 | ||
CA-222991-S | Ocular injector | Active | 20-Jan-2023 | ||
AU-2023230976-A1 | Continuous dosing regimen for treatment of a condition of the eye | Pending | 11-Mar-2022 | ||
AU-2023230975-A1 | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert | Pending | 11-Mar-2022 | ||
EP-4489749-A1 | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert | Pending | 11-Mar-2022 | A61K31/404 |
EyePoint Pharmaceuticals Signals
EyePoint Pharmaceuticals Investments & Acquisitions (3)
EyePoint Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) for . The deal was made on 17-Aug-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Aerpio Pharmaceuticals (Razuprotafib Patents and Patent Applications) | 17-Aug-2021 | Corporate Asset Purchase | Buildings and Property | ||
Icon Bioscience | 28-Mar-2018 | Merger/Acquisition | Biotechnology | ||
Control Delivery Systems | 30-Dec-2005 | Merger/Acquisition | Drug Delivery |
EyePoint Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 28, 2023
39.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

EyePoint Pharmaceuticals FAQs
-
When was EyePoint Pharmaceuticals founded?
EyePoint Pharmaceuticals was founded in 1987.
-
Where is EyePoint Pharmaceuticals headquartered?
EyePoint Pharmaceuticals is headquartered in Watertown, MA.
-
What is the size of EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals has 144 total employees.
-
What industry is EyePoint Pharmaceuticals in?
EyePoint Pharmaceuticals’s primary industry is Drug Discovery.
-
Is EyePoint Pharmaceuticals a private or public company?
EyePoint Pharmaceuticals is a Public company.
-
What is EyePoint Pharmaceuticals’s stock symbol?
The ticker symbol for EyePoint Pharmaceuticals is EYPT.
-
What is the current stock price of EyePoint Pharmaceuticals?
As of 14-Feb-2025 the stock price of EyePoint Pharmaceuticals is $6.50.
-
What is the current market cap of EyePoint Pharmaceuticals?
The current market capitalization of EyePoint Pharmaceuticals is $444M.
-
What is EyePoint Pharmaceuticals’s current revenue?
The trailing twelve month revenue for EyePoint Pharmaceuticals is $45.7M.
-
Who are EyePoint Pharmaceuticals’s competitors?
Novartis, Landsteiner Scientific, Swedish Orphan Biovitrum, Merck & Co., and Cipla are some of the 67 competitors of EyePoint Pharmaceuticals.
-
What is EyePoint Pharmaceuticals’s annual earnings per share (EPS)?
EyePoint Pharmaceuticals’s EPS for 12 months was -$1.99.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »